anti-β-amyloid monoclonal antibody

Anti-β-amyloid monoclonal antibodies are a class of biologic therapies designed to target and clear amyloid-beta (Aβ) plaques from the brain, a hallmark of Alzheimer's disease. These antibodies bind to various forms of Aβ—such as monomers, oligomers, protofibrils, or insoluble plaques—facilitating their removal via microglial phagocytosis or other clearance mechanisms. Several agents in this class, including aducanumab, lecanemab, and donanemab, have been developed and evaluated in clinical trials for their ability to slow cognitive and functional decline in patients with early-stage Alzheimer's disease. The trial ChiCTR2600127934 specifically investigates the impact of these therapies on immunometabolism and biomarker profiles in a Chinese cohort at Ruijin Hospital.

Other names

anti-Aβ antibodiesanti-amyloid beta monoclonal antibodiesanti-beta-amyloid monoclonal antibody